Clinical trials: Interleukin
Systemic-Onset Juvenile Idiopathic Arthritis
Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
1. Main objective: To test the efficacy of anakinra treatment in children or young adults with corticosteroid-resistant or -dependent Systemic-Onset Juvenile Idiopathic Arthritis (SO-JIA) 2.
- Trial name
- NCT00339157
- Testing
- Anakinra, Pneumo23
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Drug Resistant Epilepsy
The Role of Vitamin D in Neuroinflammatory on Drug Resistant Epilepsy
The incident of epilepsy still very high in Indonesia, thus many patients become drug resistant epilepsy. As vitamin D has some anticonvulsant effect, the investigators want to study if an additional dose of vitamin D can help…
- Trial name
- NCT06053281
- Testing
- Cholecalciferol
- Where
- Indonesia
- Volunteers
- 70 people
- Sponsor
- DINA KEUMALA SARI
Acne Vulgaris
Investigating the Efficacy of Oral Probiotics Versus Placebo in Pakistani Patients With Moderate Acne on Acne Lesion Count and Systemic Inflammation
This randomized controlled trial evaluates the efficacy of oral probiotics compared to placebo in Pakistani patients with moderate Acne Vulgaris.
- Trial name
- Acne vulgaris (NCT07539129)
- Testing
- Probiotics
- Where
- Pakistan
- Volunteers
- 64 people
- Sponsor
- Foundation University Islamabad
Neuroblastoma Recurrent
CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma
A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m²) for five consecutive days will be administered every 4 weeks, starting 60-180 days after previous haploidentical stem cell transplantation.
- Trial name
- NCT02258815
- Testing
- ch14.18/CHO
- Where
- 4 sites in Austria, Germany
- Volunteers
- 35 people
- Sponsor
- University Children's Hospital Tuebingen
Type 1 Diabetes Mellitus
Rilonacept in Diabetes Mellitus Type 1: Safety Study
This study is being done to see if an investigational drug called rilonacept is safe to use in patients with type 1 diabetes, and if it can slow the loss of the body's ability to secrete insulin in patients who are still able to…
- Trial name
- RID-A (NCT00962026)
- Testing
- Rilonacept
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Texas Southwestern Medical Center